๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Disposition of sulfadimethoxine in cattle: Inclusion of protein binding factors in a pharmacokinetic model

โœ Scribed by D. W. A. Bourne; M. Bialer; L. W. Dittert; M. Hayashi; G. Rudawsky; G. D. Koritz; R. F. Bevill

Publisher
John Wiley and Sons
Year
1981
Tongue
English
Weight
522 KB
Volume
70
Category
Article
ISSN
0022-3549

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Prediction of the disposition of midazol
Prediction of the disposition of midazolam in surgical patients by a physiologically based pharmacokinetic model
โœ Sven Bjรถrkman; D. Russell Wada; Britt-Marie Berling; Gรถran Benoni ๐Ÿ“‚ Article ๐Ÿ“… 2001 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 243 KB

The aim of this study was to predict the disposition of midazolam in individual surgical patients by physiologically based pharmacokinetic (PBPK) modeling and explore the causes of interindividual variability. Tissueยฑplasma partition coefยฎcients (k p ) were scaled from rat to human values by a physi

The disposition and protein binding of b
The disposition and protein binding of batanopride and its metabolites in subjects with renal impairment
โœ J. V.St. Peter; M. E. Brady; E. F. Foote; K. A. Dandekar; L. Smaldone; J. L. Pyk ๐Ÿ“‚ Article ๐Ÿ“… 1993 ๐Ÿ› Springer ๐ŸŒ English โš– 519 KB

We have studied the disposition of batanopride and its three major metabolites (the erythro-alcohol, threo-alcohol, and N-desethyl metabolites) in 27 subjects with various degrees of renal function after intravenous infusion of a single dose of 3.6.mg.kg-1 of batanopride over 15 min. The subjects we

Pharmacokinetic/pharmacodynamic modeling
Pharmacokinetic/pharmacodynamic modeling of the effects of intravenous immunoglobulin on the disposition of antiplatelet antibodies in a rat model of immune thrombocytopenia
โœ Ryan J. Hansen; Joseph P. Balthasar ๐Ÿ“‚ Article ๐Ÿ“… 2003 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 143 KB

Recently, our laboratory reported that intravenous immunoglobulin (IVIG) treatment increased antiplatelet antibody (7E3) clearance in a rat model of immune thrombocytopenic purpura (ITP). However, due to the multifaceted nature of IVIG therapy, the contribution of this increase in antiplatelet antib